Tasly Pharmaceutical Group Statistics

Total Valuation

Tasly Pharmaceutical Group has a market cap or net worth of CNY 22.47 billion. The enterprise value is 19.98 billion.

Market Cap	22.47B
Enterprise Value	19.98B

Important Dates

The last earnings date was Monday, October 28, 2024.

Earnings Date	Oct 28, 2024
Ex-Dividend Date	Oct 10, 2024

Share Statistics

Tasly Pharmaceutical Group has 1.49 billion shares outstanding. The number of shares has increased by 2.18% in one year.

Current Share Class	n/a
Shares Outstanding	1.49B
Shares Change (YoY)	+2.18%
Shares Change (QoQ)	+2.01%
Owned by Insiders (%)	0.06%
Owned by Institutions (%)	8.97%
Float	765.53M

Valuation Ratios

The trailing PE ratio is 25.60 and the forward PE ratio is 15.04.

PE Ratio	25.60
Forward PE	15.04
PS Ratio	2.63
PB Ratio	1.77
P/TBV Ratio	n/a
P/FCF Ratio	11.05
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.86, with an EV/FCF ratio of 9.83.

EV / Earnings	22.68
EV / Sales	2.33
EV / EBITDA	10.86
EV / EBIT	14.66
EV / FCF	9.83

Financial Position

The company has a current ratio of 2.70, with a Debt / Equity ratio of 0.17.

Current Ratio	2.70
Quick Ratio	2.16
Debt / Equity	0.17
Debt / EBITDA	1.18
Debt / FCF	1.07
Interest Coverage	18.04

Financial Efficiency

Return on equity (ROE) is 6.56% and return on invested capital (ROIC) is 5.44%.

Return on Equity (ROE)	6.56%
Return on Assets (ROA)	4.94%
Return on Capital (ROIC)	5.44%
Revenue Per Employee	928,676
Profits Per Employee	95,528
Employee Count	9,223
Asset Turnover	0.50
Inventory Turnover	1.66

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -0.13% in the last 52 weeks. The beta is 0.41, so Tasly Pharmaceutical Group's price volatility has been lower than the market average.

Beta (5Y)	0.41
52-Week Price Change	-0.13%
50-Day Moving Average	14.94
200-Day Moving Average	14.76
Relative Strength Index (RSI)	47.28
Average Volume (20 Days)	19,658,082

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Tasly Pharmaceutical Group had revenue of CNY 8.57 billion and earned 881.05 million in profits. Earnings per share was 0.59.

Revenue	8.57B
Gross Profit	5.71B
Operating Income	1.36B
Pretax Income	1.01B
Net Income	881.05M
EBITDA	1.76B
EBIT	1.36B
Earnings Per Share (EPS)	0.59

Full Income Statement

Balance Sheet

The company has 4.97 billion in cash and 2.17 billion in debt, giving a net cash position of 2.80 billion or 1.87 per share.

Cash & Cash Equivalents	4.97B
Total Debt	2.17B
Net Cash	2.80B
Net Cash Per Share	1.87
Equity (Book Value)	13.02B
Book Value Per Share	8.51
Working Capital	5.71B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.68 billion and capital expenditures -642.66 million, giving a free cash flow of 2.03 billion.

Operating Cash Flow	2.68B
Capital Expenditures	-642.66M
Free Cash Flow	2.03B
FCF Per Share	1.36

Full Cash Flow Statement

Margins

Gross margin is 66.70%, with operating and profit margins of 15.92% and 10.29%.

Gross Margin	66.70%
Operating Margin	15.92%
Pretax Margin	11.84%
Profit Margin	10.29%
EBITDA Margin	20.54%
EBIT Margin	15.92%
FCF Margin	23.74%

Dividends & Yields

This stock pays an annual dividend of 0.52, which amounts to a dividend yield of 3.43%.

Dividend Per Share	0.52
Dividend Yield	3.43%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	62.05%
Buyback Yield	-2.18%
Shareholder Yield	1.25%
Earnings Yield	3.91%
FCF Yield	9.05%

Dividend Details

Stock Splits

The last stock split was on June 5, 2018. It was a forward split with a ratio of 1.4.

Last Split Date	Jun 5, 2018
Split Type	Forward
Split Ratio	1.4

Scores

Tasly Pharmaceutical Group has an Altman Z-Score of 5.54.

Altman Z-Score	5.54
Piotroski F-Score	n/a